97,300 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by APG Asset Management N.V.

APG Asset Management N.V. purchased a new stake in Exact Sciences Co. (NASDAQ:EXAS) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 97,300 shares of the medical research company’s stock, valued at approximately $5,280,000.

Other hedge funds have also recently made changes to their positions in the company. Quantinno Capital Management LP bought a new stake in Exact Sciences during the third quarter valued at $223,000. Stifel Financial Corp increased its stake in Exact Sciences by 2.3% in the 3rd quarter. Stifel Financial Corp now owns 80,961 shares of the medical research company’s stock worth $5,515,000 after acquiring an additional 1,825 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of Exact Sciences by 12.4% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 51,437 shares of the medical research company’s stock valued at $3,504,000 after acquiring an additional 5,664 shares in the last quarter. M&T Bank Corp boosted its position in shares of Exact Sciences by 43.5% during the 3rd quarter. M&T Bank Corp now owns 9,256 shares of the medical research company’s stock valued at $630,000 after acquiring an additional 2,806 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Exact Sciences by 0.3% during the third quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after purchasing an additional 7,873 shares in the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Exact Sciences Trading Up 1.6 %

NASDAQ:EXAS opened at $44.45 on Friday. The firm has a market capitalization of $8.26 billion, a P/E ratio of -7.98 and a beta of 1.14. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $73.10. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company has a fifty day moving average of $46.95 and a 200 day moving average of $55.80.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. On average, research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EXAS. Piper Sandler lowered their target price on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Royal Bank of Canada started coverage on shares of Exact Sciences in a research report on Thursday, March 13th. They set a “sector perform” rating and a $52.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Scotiabank increased their target price on Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Finally, Mizuho started coverage on Exact Sciences in a research note on Thursday. They set an “outperform” rating and a $60.00 price target for the company. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Exact Sciences has an average rating of “Moderate Buy” and an average target price of $69.25.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.